Adocia SA (0QAI.L)
| Previous close | 9.83 |
| Open | 9.72 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 9.72 - 9.85 |
| 52-week range | 9.72 - 9.85 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 68.737M |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of October 31st, 2021
LYON, France, November 19, 2021--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with inno
- Business Wire
Adocia Announces 2021 Third Quarter Financial Results and a Financing of €7 Million
LYON, France, October 26, 2021--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases announced today its third quarter financial results as well as the completion, today, of a financing of EUR 7 million.
- Globe Newswire
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to AdociaBC Lispro addresses the Chinese prandial insulin market which is approx. $1.4bn today with double-digit growth LYON, France, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatments and other metab
